Navigation Links
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Date:12/9/2012

ne system to attack and destroy myeloma cells, but also prevents the growth of new blood vessels and inhibits myeloma cell growth by reducing the supply of oxygen and nutrients to the myeloma cells. To evaluate whether a combination regimen with pomalidomide plus low-dose dexamethasone therapy might offer relapsed multiple myeloma patients better progression-free and overall survival than high-dose dexamethasone alone, researchers conducted a study in a population of patients with refractory or relapsed and refractory disease.

The open-label, multicenter, Phase III trial evaluated the safety and efficacy of pomalidomide and low-dose dexamethasone (LoDEX) combination as compared to high-dose dexamethasone (HiDEX) alone. A total of 455 patients were enrolled and randomized to receive regimens of either pomalidomide with LoDEX (Arm A, 302 patients) or HiDEX (Arm B, 153 patients) in a 28-day cycle until disease progression or severe toxicity. The primary endpoint was progression-free survival (PFS), while secondary endpoints included measures of safety, overall survival, and quality of life.

After a median follow-up of 18 weeks, patients who received the pomalidomide and LoDEX combination experienced significantly longer PFS compared with those who received HiDEX alone (15.7 vs. 8 weeks), and overall survival was also longer in the combination treatment arm. After an independent review committee concluded that the combination regimen offered survival advantage, the study's Data Safety Monitoring Board recommended that patients from Arm B be switched to Arm A to receive the combination treatment.

The combination regimen was well tolerated among the study participants, although some expected toxicities were reported in both groups, including low neutrophil count (42% in Arm A vs. 15% in Arm B), low platelet count (21% vs. 24%), and fever (7% vs. 0%). At the time of analysis, 45 percent of patients in Arm A and 25 percent of patients in Arm
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Researchers develop novel 3-D culture system for inflammatory breast cancer
2. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
3. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
4. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
5. Novel breast screening technology increases diagnostic accuracy
6. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Novel treatment strategies for epilepsy
9. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
10. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
11. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
(Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... in effort to drop pounds, experts say , TUESDAY, Nov. ... exercise and diet are crucial. But a new study says ... the number of TVs in your house and the presence ... out as a stronger factor than we would have anticipated," ...
... Nov. 3 EntreMed, Inc. (Nasdaq: ENMD ... the treatment of cancer today announced presentations for ... AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ... Boston, Massachusetts. Presentations are listed below. , ...
... China, Nov. 3 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain,Drugstore Ltd. (NYSE: ... chain in China based on the number of directly operated ... agreement,with ATMU (China) Technology Co., Ltd., a subsidiary of ATMU ... ATMs in Nepstar stores. , This ...
... 44-year-old woman will celebrate many future birthdays thanks to the ... for breast cancer. , Dr. Sweeten, a board-certified gynecologist and ... incorporated the Provista Life Science BT Test®, a blood test ... practice. Sweeten noted a case where a 44-year-old patient called ...
... ... the Health IT Standards Committee hearing held in Washington, D.C. last week, which was a ... ... Health Inc. endorses and commends the efforts of the Health IT Standards Committee hearing ...
... ... Oven for PTA and PTCA Catheters is Compact, Easy to Operate and Cost Effective ... Laguna Niguel, ... provides a cost-effective approach to heat treating of wrapped balloons on balloon catheters ...
Cached Medicine News:Health News:Living With Less TV, More Sweat Boosts Weight Loss 2Health News:Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference 2Health News:Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference 3Health News:China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores 2Health News:China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores 3Health News:A Breast Cancer Test That Saves Lives 2Health News:A Breast Cancer Test That Saves Lives 3Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 2Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 3Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 4Health News:Interface new Balloon Catheter Solutions PTA and PTCA Catheters 2
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... 14, 2014 The Brandeis Medical Center, led by Dr. ... premier and affordable laser tattoo removal experience with the advanced Astanza ... in providing high quality cosmetic services with cutting edge medical technology ... Southern California has seen a dramatic increase in ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Top plastic surgeon , Dr. David Shafer , ... and body cosmetic surgery simulation at his New York City office. ... mommy makeover , facelift , rhinoplasty and ... http://photos.prnewswire.com/prnh/20111025/NY92188 ) With his creation of the world,s ...
... N.J., Oct. 25, 2011 Omthera Pharmaceuticals, Inc., a ... J. Maines has joined the Company as Vice President ... to Chief Operating Officer, Drs. Ben Machielse, Mr. Maines ... at Omthera.   Mr. Maines brings to ...
Cached Medicine Technology:Top Plastic Surgeon Introduces World's First VECTRA XT 3D Imaging Solution 2Top Plastic Surgeon Introduces World's First VECTRA XT 3D Imaging Solution 3Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality 2
Straight shafts with 4 mm platform. Wide serrated handle with dull finish. Platform straight....
Curved shafts with 2 mm angled platform. Wide serrated handle with dull finish....
Straight shafts with micro tips and sandblast finish. Insulated smooth handle....
Double-ended. 12 mm bayonet shaped blade. 10 mm curved blade....
Medicine Products: